Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by A. Viejo
Prs38 - Cost-Consequence Analysis of Fluticasone Furoate/Vilanterol for Asthma Management in Spain: An Analysis Based on the Salford Lung Study in Asthma
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Prs48 - Cost – Effectiveness Analysis of Vilanterol/Fluticasone Furoate for Asthma Treatment in the Russian Federation
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost–consequence Analysis of Fluticasone Furoate/Vilanterol 92/22 MCG for the Management of COPD in the Spanish NHS
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Integrated Safety and Efficacy Analysis of Once-Daily Fluticasone Furoate for the Treatment of Asthma
Respiratory Research
Pulmonary
Respiratory Medicine
Benefit and Safety of Fluticasone Furoate/Vilanterol in the Salford Lung Study in Chronic Obstructive Pulmonary Disease (SLS COPD) According to Baseline Patient Characteristics and Treatment Subgroups
Respiratory Medicine
Pulmonary
Respiratory Medicine
Once-Daily Fluticasone Furoate/Vilanterol Combination Versus Twice-Daily Budesonide/Formoterol Combination in the Treatment of Controlled Stable Asthma: A Randomized Crossover Trial
Journal of Asthma and Allergy
Immunology
Pulmonary
Allergy
Respiratory Medicine
Fluticasone Furoate/Vilanterol Once Daily Improves Night-Time Awakenings in Asthma Patients With Night Symptoms; Post-Hoc Analyses of Three Randomized Controlled Trials
Journal of Asthma
Child Health
Allergy
Perinatology
Immunology
Medicine
Pediatrics
Pulmonary
Respiratory Medicine
A Randomised Trial of Fluticasone Furoate/Vilanterol (50/25 Μg; 100/25 Μg) on Lung Function in COPD
Respiratory Medicine
Pulmonary
Respiratory Medicine
Fluticasone Furoate: Once-Daily Evening Treatment Versus Twice-Daily Treatment in Moderate Asthma
Respiratory Research
Pulmonary
Respiratory Medicine
Reduction in All-Cause Mortality With Fluticasone Furoate/Umeclidinium/Vilanterol in COPD Patients
American Journal of Respiratory and Critical Care Medicine
Pulmonary
Critical Care
Respiratory Medicine
Intensive Care Medicine
